Research

*November 2021* Note: We have been told that there is travel reimbursement for this trial, both for the patient and the caregiver — so interested parties should not be deterred due to travel expenses and should contact the individual trial locations/contacts to learn more. From Blueprint Medicines: Currently, there are no…

*September 2021* Results from the IMpower133 and CASPIAN trials gave the small-cell lung cancer (SCLC) community something to cheer about: Both studies showed benefit with add-on PD-L1 blockade -- atezolizumab (Tecentriq) and durvalumab (Imfinzi), respectively -- and both of those agents are now part of front-line SCLC care. But initial…

*September 2021* Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1,2,3. Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations4,5,6. However, effective therapies have not been identified for additional EGFR mutations. Furthermore,…

*September 2021*      

*September 2021* Poziotinib, administered once daily at 16 mg, induced a median tumor reduction of 35% in patients with treatment-naïve non–small cell lung cancer (NSCLC) harboring HER2 exon 20 mutations, according to findings from cohort 4 of the ongoing phase 2 ZENITH20 trial (NCT03318939) that were presented at the 2021 ESMO Congress.1…

*September 2021* Discussing the case for antibody drug conjugate (ADC) or tyrosine kinase inhibitor TKI for HER2 mutated lung cancer at ESMO 2021:⁦    

*September 2021* Dato-DXd is an ADC targeting TROP2 and delivering a potent topoisomerase I inhibitor. Efficacy seen in prior reports but this presentation focused on the subset of patients with NSCLC harboring an actionable driver alteration. (Dr. Stephen V. Liu)   Safety/Toxicity: Grade 3+ treatment emergent adverse events (TEAEs) seen in 38% of…

*September 2021* Encouraging preliminary findings from two ongoing studies of combination therapy with amivantamab plus the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib were presented today at the ESMO Congress 2021, offering novel promise to a patient population that has a high unmet need for new treatments, particularly in later-line…

*September 2021* DZD9008 is an orally bioavailable irreversible EGFR inhibitor being developed for EGFR and HER2 mutant NSCLC. This analysis is of the WU-KONG1 and WU-KONG2 trials and presented by Dr. Pasi Janne. Efficacy set included 56 patients (18 escalation, 38 expansion), all pretreated, 25 with prior EGFR TKI therapy, 7…